Undisclosed Precision Biologic
Autoimmune Disease
Pre-clinicalActive
Key Facts
About Rhapsogen
Rhapsogen is an early-stage, private biotech firm leveraging insights from oncology and small molecule drug discovery to create precision biologics for autoimmune diseases. Founded in 2020 and based in Cambridge's vibrant biotech hub, the company is in a pre-clinical, pre-revenue stage, developing a novel therapeutic candidate with the goal of achieving best-in-class profile. While specific pipeline details and leadership are not publicly disclosed on its minimal website, the company's stated focus on a high-need area with a precision approach positions it in a competitive but potentially lucrative market segment.
View full company profileTherapeutic Areas
Other Autoimmune Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Fusion Immunotherapeutic | HCW Biologics | Clinical Trial |
| Autoimmune Disease Program | Carisma Therapeutics | Discovery |
| Not Specified (Autoimmune Focus) | Narwhal Bio | Pre-clinical |
| First-in-class autoimmune disorder target | Genesis Therapeutics | Pre-clinical |
| GIM-407 | Georgiamune | Preclinical |
| Autoimmunity Program | Accipiter Biosciences | Preclinical |
| Undisclosed Autoimmune Program | TianTi Biotherapeutics | Preclinical |
| Undisclosed Transcription Factor | Talus Bioscience | Discovery |
| Appus | BioVectis | Pre-clinical |
| Leap 1121 | Ability Biotherapeutics | Preclinical |
| ALLO-329 | Allogene Therapeutics | Phase 1 |